Skip to main content
. Author manuscript; available in PMC: 2021 Mar 23.
Published in final edited form as: J Immunol Methods. 2013 Nov 23;402(1-2):57–70. doi: 10.1016/j.jim.2013.11.011

Fig. 1. Effects of the Capture Antigen on GMAb ELISA Performance.

Fig. 1.

A. Non-Glycosylated Versus Glycosylated GM-CSF Capture Antigen. Serum GMAb concentration measured with the GMAb ELISA using GM-CSF produced in E. Coli (non-glycosylated form) or in yeast (glycosylated form). Each symbol represents the mean of 2 determinations on serum samples from each autoimmune PAP patient or healthy person (n = 20 and 10, respectively). The GMAb concentration measured for each sample with each capture antigen was not different (P=0.796, n = 30; Mann-Whitney Rank Sum Test).

B. Bland and Altman Analysis. All data shown in panel A were evaluated by Bland and Altman analysis as described in the methods.

C. Source of E. coli-derived GM-CSF Capture Antigen. ELISA plates were coated with GM-CSF (1 μg/ml) produced in E. coli obtained from several suppliers (1–5) and then used in the GMAb ELISA with sham samples (i.e., buffer instead of serum) to determine the effect on background optical absorbance. Each bar represents the mean (±SD) of 4 separate determinations. The background absorbance was different for all comparisons except between suppliers 1, 4, and 5 (P < 0.001, n = 4 each; ANOVA with pairwise multiple comparison procedures by the Holm-Sidak method).

HHS Vulnerability Disclosure